Share Cafe Interview with Dr Charmaine Gittleson
Webinar Presentation by Mark Diamond – ShareCafe
Small Cap Hidden Gems Webinar
An interview with Duchenne Muscular Dystrophy expert Prof Thomas Voit – Shane Storey, Wilsons Equity Research
Morgans Desk Note 25 May 2020
Bioshares Report 25 May 2020
Under the Microscope – Morgans Senior Analyst Scott Power, spoke with Mark Diamond the CEO of Antisense Therapeutics (ANP) following the release of the positive Phase 2 Duchenne Muscular Dystrophy clinical trial results.
Bioshares Report – 18 December 2019
Stockhead TV – 90 seconds with Mark Diamond
Proactive Interview with CEO Mark Diamond: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102
Managing Director and CEO Mark Diamond provides an update on the company’s progress particularly around the Duchenne Muscular Dystrophy trial being undertaken in Australia.
ANP: Why partnering with big biotech has its benefits
Breakthrough Prize given to Antisense pioneer
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Antisense Therapeutics could fill Duchenne Muscular Dystrophy treatment gap
Biotech Daily_Dr Boreham’s Crucible
Under the Microscope Antisense Therapeutics, Mark Diamond, Chief Executive Officer
Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?